Clinical Trial Detail

NCT ID NCT02264990
Title Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AbbVie
Indications

lung non-small cell carcinoma

Therapies

Pemetrexed

Carboplatin

Paclitaxel

Veliparib

Cisplatin

Age Groups: adult

Additional content available in CKB BOOST